<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">INSULIN LISPRO</span><br/>(in'su-lin lis'pro)<br/><span class="topboxtradename">Humalog<br/></span><b>Classifications:</b> <span class="classification">hormone and synthetic substitute</span>; <span class="classification">antidiabetic agent</span><br/><b>Prototype: </b>Insulin Injection<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 units/mL</p>
<h1><a name="action">Actions</a></h1>
<p>Insulin lispro of recombinant DNA origin is a human insulin that is a rapid-acting, glucose-lowering agent.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>It lowers blood glucose levels by increasing peripheral glucose uptake, especially by skeletal muscle and fat tissue, and
         by inhibiting the liver from changing glycogen to glucose. One unit of insulin lispro has the same glucose-lowering ability
         as human regular insulin, but the effect is more rapid and of shorter duration.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of diabetes mellitus.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>During episodes of hypoglycemia or in patients sensitive to any ingredient in the formulation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>In insulin resistant patients, hyperthyroidism or hypothyroidism; lactation, older adults, pregnancy (category B), renal or
         hepatic impairment. Safety and efficacy in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Diabetes Mellitus (type 1)</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 510 U 015 min a.c. (dose adjustments based on blood glucose determinations)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>Give 015 min before meals.</li>
<li> 				Note: May be given in same syringe with longer-acting insulins but absorption may be delayed. 			</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1>(see <small>INSULIN INJECTIONS, REGULAR</small>). 
      <h1><a name="interactions">Interactions</a></h1>(see <small>INSULIN INJECTION, REGULAR</small>). 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from IM and SC injection sites. <span class="typehead">Onset:</span> Peak: 0.51 h. <span class="typehead">Duration:</span> 34 h. <span class="typehead">Distribution:</span> Throughout extracellular fluids. <span class="typehead">Metabolism:</span> Metabolized in liver with some metabolism in kidneys. <span class="typehead">Elimination:</span> Half-Life: Biological, up to 13 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p>(see <small>INSULIN INJECTION, REGULAR)</small>
</p>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Assess for hypoglycemia from 1 to 3 h after injection.</li>
<li>Assess highly insulin-dependent patients for need for increases in intermediate/long-acting insulins.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li> 							Note: Risk of hypoglycemia is greatest 13 h after injection. 						</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>